Meza-Espinoza JP, Gutiérrez-Angulo M, Vázquez-Cárdenas A, Delgado-Lamas JL, Esparza-Flores MA, González-García JR

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 338-341
Archivo PDF: 88.11 Kb.

RESUMEN

Con el objetivo de conocer la proporción de los transcritos b2a2 y b3a2 de BCR/ABL1, nosotros realizamos estudios de RT-PCR en 93 pacientes mexicanos con Leucemia Mieloide Crónica. Cuarenta y cinco pacientes (48%) mostraron el transcrito b3a2, 37 individuos (40%) el transcrito b2a2 y en 11 casos (12%) ambos transcritos fueron detectados. Análisis estadísticos muestran que estas cifras concuerdan con dos de tres estudios similares realizados en población mexicana. Por otra parte, diferencias significativas en las frecuencias de los transcritos fueron encontradas entre la población mexicana y pacientes de otros países (Ecuador, Inglaterra, Italia, Polonia, Japón y Tailandia). Los pacientes ecuatorianos mostraron diferencias con todas las poblaciones analizadas. Estas variaciones pudieran ser debidas a un componente genético diferente.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-72.

2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic mieloyd leukemia. Blood 2000; 96: 3343-56.

3. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-9.

4. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia specific p210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212-4.

5. Arana-Trejo RM, Ruiz-Sanchez E, Ignacio-Ibarra G, Baez de la Fuente E, Garces O, et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol 2002; 24: 145-50.

6. Rosas-Cabral A, Martinez-Mancilla M, Ayala-Sanchez M, Vela-Ojeda J, Bahena-Resendiz P, Vadillo-Buenfil M., et al. Analysis of bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia. Gac Med Mex 2003; 139: 553-9.

7. Ruiz-Argüelles GJ, Garces-Eisele J, Reyes-Nuñez V, Ruiz-Delgado GJ. Frequencies of the breakpoint cluster region types of the BCR/ABL fusion gene in Mexican Mestizo patients with chronic myelogenous leukemia. Rev Invest Clin 2004; 56: 605-8.

8. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995; 89: 546-54.

9. Inokuchi K, Inoue T, Tojo A, Futaki M, Miyake K, Yamada T, Tanabe Y, Ohki I, Dan K, Ozawa K, Asano S, Nomura T. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood 1991; 78: 3125-7.

10. Udomsakdi-Auewarakul C, U-Pratya Y, Boonmoh S, Vatanavicharn S. Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR). J Med Assoc Thai 2000; 83: 928-35.

11. Prejzner W. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia. Med Sci Monit 2002; 8: BR193-7.

12. Seferynska I, Brojer E, Sankowska M, Majewski M, Maj S. A relationship between the breakpoint of the bcr gene and some hematologic parameters in patients with chronic myelogenous leukemia. Acta Haematol Pol 1995; 26: 385-91.

13. Martinelli G, Testoni N, Montefusco V, Amabile M, Saglio G, Ottaviani E, et al. Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis. Haematologica 1998; 83: 593-601.

14. Cervantes F, Colomer D, Vives-Corrons JL, Rozman C, Montserrat E. Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia 1996; 10: 1241-3.

15. Paz-y-Mino C, Burgos R, Morillo SA, Santos JC, Fiallo BF, Leone PE. BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America. Cancer Genet Cytogenet 2002; 132: 65-7.

16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.

17. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, de Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-74.

18. Branford S, Hughes TP, Rudzki Z. Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. Br J Haematol 2002; 117: 875-7.

19. Inokuchi K, Nomura T. The relationship between the type of bcr-abl hybrid messenger RNA and thrombopoiesis in Philadelphia-positive chronic myeologenous leukemia. Leuk Lymphoma 1993; 10: 9-15.

20. Fioretos T, Nilsson PG, Aman P, Heim S, Kristoffersson U, Malm C, Simonsson B, Turesson I, Mitelman F. Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia. Leukemia 1993; 7: 1225-31.

21. Colleoni GW, Silva MR, Silva RS, Costa FF, Kerbauy J, Saad ST. Relationship between the type of BCR-ABL rearrangement and bone marrow histopathological features in chronic myeloid leukemia. Acta Oncol 1997; 36: 313-5.

22. Opalka B, Wandl UB, Stutenkemper R, Kloke O, Seeber S, Niederle N. No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia. Blood 1992; 80: 1854-5.

23. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, et al. The possible influences of B2A2 and B3A2 BCR/ ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000; 36: 1395-401.

24. Rozman C, Urbano-Ispizua A, Cervantes F, Rozman M, Colomer D, Feliz P, Pujades A, Vives Corrons JL. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia 1995;9:1104-7.